Why Benzodiazepines Fell Out of Favor for Sleep

What benzodiazepines are actually being used for here

Benzodiazepines belong to a class sometimes called benzodiazepine receptor agonists (BZRAs), medications that act on the same brain receptor system to produce sedation, and that class has long been used for insomnia, among other things, alongside newer non-benzodiazepine "Z-drugs" that work through a related mechanism. For a long stretch of time, a benzodiazepine was simply what "a sleeping pill" meant to most people, prescribed readily for everything from a rough week to years of ongoing insomnia.

Benzodiazepine receptor agonist is the umbrella term clinicians use for this whole family, because it groups drugs by how they act on the brain rather than by their chemical structure — which is also why guidance about one member of the family often extends to the others.

That readiness to prescribe was, in part, a product of timing: for decades, a well-studied behavioral alternative simply was not as widely available or as well-documented as it is now. As the evidence behind cognitive behavioral therapy for insomnia accumulated, and as the harms of long-term benzodiazepine use became clearer through longer follow-up studies, the calculation for a chronic, ongoing sleep problem shifted.

Why the shift did not happen overnight

Population studies of insomnia consistently find that roughly a third of adults report at least some insomnia symptoms, with meaningful daytime consequences in a smaller but still substantial share 1Ref 1Ohayon MM (2002).Epidemiology of insomnia: what we know and what we still need to learn.That about a third of adults report insomnia symptoms, with 9-15% having insomnia with daytime consequences, supporting the scale of the underlying problem, not current diagnostic criteria.. A problem that common does not change its standard treatment quickly, because habits, training, and prescribing patterns built up over decades do not reverse on the strength of one guideline. What changed was the accumulation of longer-term outcome data specifically on continued benzodiazepine use, which made the tradeoff between short-term relief and long-term harm harder to ignore, particularly once it was compared directly against a therapy option with durable results.

Why long-term use is now actively discouraged

An evidence-based deprescribing guideline recommends that clinicians offer to taper benzodiazepines and z-drugs used for insomnia, particularly in adults 65 and older, because the harms of continued use — falls, fractures, and cognitive impairment — outweigh the benefit for most long-term users, and it names cognitive behavioral therapy for insomnia as the recommended alternative 2Ref 2Pottie K, Thompson W, Davies S, et al. (2018).Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.That clinicians are recommended to offer a gradual taper of benzodiazepines and z-drugs used for insomnia, especially in adults 65+, due to falls and cognitive-impairment harms, with CBT-I as the recommended alternative, decided through shared decision-making rather than abrupt discontinuation.. That is a guideline actively recommending a change in a treatment already underway, which is a stronger statement than simply preferring one option over another from the start.

This is a guideline about long-term, ongoing use. It is not a guideline that says a short course was the wrong call at the time. The concern about hypnotics fall fracture risk elderly is specifically about the cumulative effect of continued use, not a single dose taken during an acute crisis.

The evidence that shifted the calculus: a head-to-head trial

One randomized trial that put this to a direct test enrolled older adults with chronic insomnia and compared cognitive behavioral therapy against zopiclone, a non-benzodiazepine hypnotic in the same broader BZRA family 3Ref 3Sivertsen B, Omvik S, Pallesen S, et al. (2006).Cognitive Behavioral Therapy vs Zopiclone for Treatment of Chronic Primary Insomnia in Older Adults: A Randomized Controlled Trial.That CBT-I outperformed the hypnotic zopiclone on polysomnographic sleep efficiency and slow-wave sleep at short- and six-month follow-up, with zopiclone no better than placebo long-term, in older adults.. Measured objectively with polysomnography, CBT-I produced better sleep efficiency and more slow-wave sleep than the drug, both right after treatment and six months later — and by that six-month mark, zopiclone performed no better than a placebo pill 3Ref 3Sivertsen B, Omvik S, Pallesen S, et al. (2006).Cognitive Behavioral Therapy vs Zopiclone for Treatment of Chronic Primary Insomnia in Older Adults: A Randomized Controlled Trial.That CBT-I outperformed the hypnotic zopiclone on polysomnographic sleep efficiency and slow-wave sleep at short- and six-month follow-up, with zopiclone no better than placebo long-term, in older adults..

A drug that is no better than placebo after six months, while therapy still shows a durable benefit, is the kind of finding that reshapes a field's default recommendation 3Ref 3Sivertsen B, Omvik S, Pallesen S, et al. (2006).Cognitive Behavioral Therapy vs Zopiclone for Treatment of Chronic Primary Insomnia in Older Adults: A Randomized Controlled Trial.That CBT-I outperformed the hypnotic zopiclone on polysomnographic sleep efficiency and slow-wave sleep at short- and six-month follow-up, with zopiclone no better than placebo long-term, in older adults..

The z-drug boxed warning — related, but not the same drugs

It is worth being precise here: the FDA's 2019 boxed warning for serious injuries from complex sleep behaviors — sleepwalking, even sleep-driving, occurring after a single dose — was placed on the z-drugs eszopiclone, zaleplon, and zolpidem, not on classic benzodiazepines like temazepam or diazepam 4Ref 4US Food and Drug Administration (2019).Certain Prescription Insomnia Medicines: New Boxed Warning — Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake.That the FDA's 2019 boxed warning for complex sleep behaviors applies specifically to the z-drugs eszopiclone, zaleplon, and zolpidem, not to classic benzodiazepines.. They are chemically distinct, even though both families work on overlapping brain receptors and both raise dependence concerns with long-term use. Conflating "a sleeping pill" with "a benzodiazepine" is common, but the two families carry somewhat different, specific warnings, and it is worth knowing which one is actually being discussed.

That distinction matters in practice, too: a person switched from a benzodiazepine to a z-drug has not necessarily traded a risky medication for a safer one, only for one with a different, better-documented risk. Neither substitution addresses the underlying reason chronic insomnia is still there once the pill wears off.

Where a benzodiazepine still has a reasonable case

None of this means a benzodiazepine is never appropriate. A short course for acute, situational insomnia — grief, a medical crisis, an unusually stressful stretch with a clear endpoint — is a different clinical decision from an open-ended prescription for chronic insomnia, and the deprescribing concern is squarely about the latter 2Ref 2Pottie K, Thompson W, Davies S, et al. (2018).Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.That clinicians are recommended to offer a gradual taper of benzodiazepines and z-drugs used for insomnia, especially in adults 65+, due to falls and cognitive-impairment harms, with CBT-I as the recommended alternative, decided through shared decision-making rather than abrupt discontinuation.. The sleep-medication conversation worth having is less about whether the drug class is good or bad in the abstract, and more about how long a particular course is expected to last and what happens when that stretch ends.

If you have been taking one for a long time

The guideline's own language is to offer a taper, not to demand an abrupt stop — shared decision making hypnotics is the deliberate phrase used, meaning the person taking the medication and the prescriber work out the pace together 2Ref 2Pottie K, Thompson W, Davies S, et al. (2018).Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.That clinicians are recommended to offer a gradual taper of benzodiazepines and z-drugs used for insomnia, especially in adults 65+, due to falls and cognitive-impairment harms, with CBT-I as the recommended alternative, decided through shared decision-making rather than abrupt discontinuation.. Stopping a long-used benzodiazepine abruptly, rather than gradually and with medical guidance, is exactly the scenario the guideline is written to avoid, since abrupt discontinuation is where rebound insomnia and withdrawal effects are most likely to appear.

Why CBT-I became the recommended alternative, not just "an" alternative

The AASM CBT-I first line recommendation for chronic insomnia is a strong one, built from components such as sleep restriction therapy and stimulus control delivered together, and it is the reason clinicians increasingly lead with therapy rather than a prescription when insomnia is expected to be a long-term problem 5Ref 5Edinger JD, Arnedt JT, Bertisch SM, et al. (2021).Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline.That multicomponent CBT-I, including stimulus control and sleep restriction as components, carries a strong recommendation for chronic insomnia.. Other borrowed-for-sleep options exist too, including gabapentin for sleep used off-label and otc pm sleep aids sold without a prescription at all, but none of them changes the core reason benzodiazepines specifically fell from favor: an alternative with a better long-term track record, and none of the same dependence risk, became available and well-studied.